Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

HAE Speaks

HAE Speaks artwork

Gene Therapy in HAE: A look into BioMarin’s Investigational Study

Feb 6, 202317 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode, BioMarin’s Clinical Science Lead, Jack Brownrigg, and HAE physician, Dr. Timothy Craig, discuss AAV Gene Therapy and BioMarin’s investigational clinical trial for HAE. For more information about Hereditary Angioedema please visit HAEA.org This episode is brought to you by our sponsor: BioMarin Pharmaceutical Inc.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Hi there, I'm Jack Brown Drake. I work in clinical development at buy more in which is a biotechnology company that develops and commercializes treatments for genetic diseases. And I'm joined today by Tim greig. An allergist or immunologist and leader. In the field of hereditary angioedema at Penn State. Warm welcome to 10. My yeah, I'm doing well. Thank you, Jack. I should start by saying that the podcast is sponsored by buying more in and Tim. And I have so excited to provide listeners from the AHA.

A community with an overview of gene therapy research. We're going to discuss what gene therapy is. Why this investigational approach to treatment is different, perhaps from existing Therapies in hereditary, angioedema. And finally, how it's being studied in the clinical trial setting for Hae I should also note before we begin that no Gene therapies. For Hae has been determined to be safe or indeed effective and therefore none are approved for use.

And several companies are conducting Research into different types of genetic therapies for Hae. I'm going to thought Tim Boston, your question, which is, can you give an introduction to genes and describe what their relevance is to this disease? Ha, you likely know that genes play a very important part and who we are, you know, our hair color or curly or straight, or eye color, many, many things that we look at when we look at people is secondary to our

genes, but a genes play a lot, a larger role than just how we look So our blood cells had determined by genes, or liver cells are determined by genes. And that's so important in jeans are made up of DNA and we'll come back to what DNA is it a little bit when Jack talks about therapy? These DNA are like a map. If you want to say of how different protein should be made and how proteins congregate to form organs and who we are. And that's very important that

Cell has genes in it, that kind of decide how that sells going to react and what proteins are going to it's going to produce. So it's very, very important to know the idea that genes are made a DNA. And that DNA is the roadmap for the proteins that make us who we are in the case of Hae, it's very important as well. So we know that Hae type 1, which is what low protein. What happens to genes are abnormal a Neighs abnormal. The protein folds up.

Normally it doesn't get secreted. So the proteins low. And with that two functions, low and C4 is low and they have the manifestation, so you had two manifestations of Hae in type 2. It's a little different, the folding occurs because of the DNA roadmap but what happens the enzymatic of the active head is not effective and so here the protein can be normal in levels but in function its poor and so you still have the same man. Office stations as someone who has a lack of protein. So it's very, very important

that the DNA Directed what? The proteins will be in an Hae. Those proteins are defective and so one of the things, you know, we think about is, if you can modify DNA how that will help us, because what's happened in people have Hae, there was a mutation in that DNA lead and Taro how their symptoms are developed because of the lack of the protein that the genes direct to make. Brilliant. Thanks, thanks to him. That's very clear.

And why why the interest for gene therapy research or investigating this particular treatment modality it in people with h a year. So in Hae again, it's the lack of protein or defective protein of needs to the recurrence, well in the belly pain, this one of the upper Airway and it is a genetic condition absence. Sort of genes or abnormal genes is what causes the protein to be?

Abnormal, if you want to use that term in the case of Hae investigation of gene therapy that will be discussing later, may be able to reinstate that copy of genes and that gene is called the serpent one gene so that can make appropriate protein. And that's hoping that you'll reinstate a normal activity or semi normal activity of the machineries of the protein is made and decreases the signs and symptoms. Is of hereditary, angioedema.

Hey Jack. Can you explain gene therapy in Greater detail for those people who are listeners? Sure I'll try and demystify what's in the gene therapy medicine and then perhaps took a bit about the objectives of a study to investigate this particular, treatment option in around 300 IMA. So in the ongoing by Marin study, which is called Harmony one gene therapy is being researched and it uses a biological delivery package and

that delivery package is designed to transport the gene. In this case, as Tim said, sir can G1 to its destination, which is the liver cells because that's where C1 inhibitor. Protein is normally made Now this delivery package is made of a naturally occurring virus called adeno-associated virus or AV for sure. And this particular virus has been modified to remove its own DNA. And that DNA is substituted with a working copy of a human,

serpent g1g alongside some instructions for the cell to actually manufacture the protein, and their AV delivery package if you like, is, is chosen, because it's not known to cause disease. He's and humans, but it's also naturally predisposed or has a natural tendency to travel to the liver cells where it's needed. So in the study many copies of this delivery package containing a certain G1 Gene are delivered by an infusion into a vein and

they travel through the circulation to the liver and what the trial is really testing is whether the liver cells are able to bring that delivery package inside the cell unpack, it and use the serpent G1 Gene contained inside to actually begin to manufacture the protein. Using the What his own machinery? And, of course, we're also measuring any side effects that occur in response to treatment both in the short term but also

for an extended period of time out 25 years. And what the trial is really testing is whether the liver cells are able to bring that delivery package inside the cell unpack, it and use the serpent G1 Gene contained inside to actually begin to manufacture the protein, using the bodies. Own machinery. And, of course, we're also measuring any side effects that occur in response to treatment both in the short term but also for an extended period of time

Mount 25 years. Tim can you speak to the ongoing by more in harmony clinical study you're an investigator in the study perhaps you could share with the audience, what it might involve for them to participate in this study. Yeah. Jack before I do that I was just wondering. You can you clarify? So it does not. Not affect the person's own DNA, their own genes, is that correct? So, that that is not a possibility that could be damaged in a chromosomes from gene therapy that you're

utilizing. Destroy the intention of the gene therapy is not to become part of your own DNA. The idea is that the DNA from the gene therapy, persists, alongside your own DNA, but it is not incorporated into our own DNA. That's the intent. Okay, that's a good point to clarify. I think so. How many one is to evaluate the safety of a single of administration of gene therapy?

You have to receive in the gene therapy, the intent. Is that your genes will induce that cell to produce the protein. And then the protein would decrease the symptoms and signs of hereditary angioedema, the study drug is called BMN 331. It's designed to Target the root cause of Hae and is given as a single dose delivered via IV or intravenous therapy as an investigational therapy. The drug has not been approved at this time by the health

authorities for public use and it's only available by clinical research. The hominid, one study will be a long-term study of left about five years. After receiving the study drug and is divided into three types. Or should I say types? I should use the word parts. Part 1 is the initial assessment to ensure that you're eligible for the study. So you need to have hereditary angioedema type 1 and type 2. You need to have your blood checks to make sure you live is working.

Well, you need to have an ultrasound scan of your liver and you need your doctor to go through your General Health and your medications and your attack history of hereditary. Angioedema, part. 2 is when you receive the study drug, to study drug, is given it a Pacific Center. So that all the participated centers will actually be given a drug. But when you go to that Center, you'll have your reimbursement for your travel and for your larger and so on, it's given by a continuous intravenous infusion. And it only be once during the

course of therapy during those five years. Years, depending on the weight and the dose needed. The infusion to be anywhere from one hour to up to 50 hours in most cases. However, it's between two and eleven point five hours, you'll need to stay overnight for observation, and of course, there'll be a bed provided and will be a comfortable situation. And that's because you have to be observed for at least eight hours after the infusion. Prior to the infusion to study drug.

You will receive two medications. These are precautionary to ensure safety and they include a short-term IV injection of routine. Hereditary angioedema, drugs in particular C1 inhibitor but also along with storage in the steroids will be given for 16 weeks, following treatment. Quad three of the study is the major part that follows the infusion and goes on for quite a long period of time to ensure safety and good control of your disease. So part three is called follow

up, you know, last up to five years and involves regular check-ups which become less frequent the further from the infusion. As you progress through this study these checkups maybe donate your study center or clinic or most of them hopefully will be done at home. Avoiding the Instead of being seen in clinic the need to attend Clinic, depends on the type of visit needed. Your study site will let you know, which can be done at home or require in clinic visits. Who can join us study?

And that's very important that anybody can join this study. You may qualify for Harmony One study. If you are 18 years of age and older, you're diagnosed of either type, 1 or type 2 hereditary angioedema, which are the deficiency of C1. Inhibitor protein, you use prophylactic medications to prevent data attacks or on-demand medications for Hae attack. So you can either be on long-term prophylaxis or Or just on treatment has needed. You have a history of at least

one Hae attack per month on average. This could be before treatment with Hae medications to use to prevent attacks. In other words, if you had two or three attacks per month and then you went on a one of the newer medications and now, you're not having any attacks. We can use that retrograde data to determine that you qualify for the study additional requirements. Apply as well. Well and the doctors will go through that as well as the nurse investigators you study

doctor will determine if you meet all the requirements and help answer any questions you may have. But those who do qualify as we've discussed participation last about five years. After receiving, the study drug participation includes a review of medical history and current and previous medications, medical, assignments, such as the physical exam, limb liver, Imogen and blood tests prior to treatment, single dose of study drug as an intravenous infusion.

As I talked about before, Weekly home health care provider or site visits in your clinic for 24 weeks. After treatment, periodic study attendance at the study Clinic after treatment Hae attack report Enver, electronic Diaries Abstinence from alcohol for one year, use of Highly Effective, contraception for women of childbearing, potential for the

duration of the study that is five years. Comprehensive overview of for participating in the study might involve people who are potentially interested, that's great. Now, you have a study site in Hershey Pennsylvania in your practice, but for those listening, perhaps in other parts of the US How can they find out more about where the study is taking place and whether they have a site near home? Yeah. So there's a few, there's

multiple centers throughout the country so it's eyes in Hershey Pennsylvania, there's one in st. Louis Missouri, one in San Diego. California is one in Cincinnati, Ohio, and Columbus, Ohio. There's a Durham North Carolina site a Dallas, Texas, site, Birmingham, Alabama, side, Right? And a Madison Mississippi site. So there's multiple sites around the country to make it easier to find the clinic to tear for you. If you are interested and think

you may be a good candidate for this trial, you can visit hey, Gene study.com and I'll spell that out. That's Hae geneva-2 Ste, you dyo, lowercase.com and you can speak with physician or contact the Hae a to be. He referred to a center or site. So jacked, you have any further things that you need to add at this time? I think perhaps the only thing I'd add is that sometimes news

sites are coming online. So important if there is is their first of all, if there isn't a site which is near where your home is, the study can accommodate your travel to a site and a lot of your follow-up can be done actually in the home setting. So a nurse can come and visit your home and do a lot of follow-up. So you don't necessarily have to go back to the site very frequently. The second thing I would say is that as we have New study sites coming online all the time. So it's worth checking the website to keep up to date on

new sites. I just wanted to close by saying huge thanks to Tim for your time and for sharing some information for potentially interested participants and audience members for this Hae a podcast. We really appreciate it. Thank you so much. I'm excited to follow the study along and to see the results. So again it's a pleasure to To be here. To be here.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Less Stress, More Joy! Holiday Wellness Tips from the HAEA Health Team!

    Nov 3, 20265 minAudio

    The holidays can be a wonderful time for joy and connection, but they can also bring added stress. Join the HAEA Health Team for practical tips to manage holiday stress, prioritize your well-being, and enjoy meaningful...

    Credit the people on this episode

  2. Nina's HAE Treatment Journey

    Oct 21, 202637 minAudio

    This month’s episode of HAE Speaks provides insight into living with hereditary angioedema (HAE) and treatment with TAKHZYRO® (lanadelumab-flyo), a prescription medicine used to prevent attacks of HAE in people two...

    Credit the people on this episode

  3. Choosing Coverage with Confidence: An HAE Patient's Guide to Open Enrollment with CSL

    Oct 6, 202624 minAudio

    Learn what to consider when choosing a health insurance plan during Open Enrollment. The conversation covers medication coverage, prior authorizations, specialty pharmacies, out-of-pocket costs, provider networks, and...

    Credit the people on this episode

  4. End of Year Legislative Update: What it Means for the HAEA Community

    Oct 6, 202618 minAudio

    In this episode, HAEA Advocacy Director, Jess Myers, sits down with Dane Christiansen, the Managing Partner of the Health and Medicine Counsel of Washington, for a special end-of-year legislative update. Together, they...

    Credit the people on this episode

  5. Transitioning to Medicare: Helpful Insights from the HAEA Health Team

    Oct 6, 20268 minAudio

    In this episode, two compassionate advocates for the health and wellbeing of our community, Troyce Venturella, HAEA Director of Health & Research Services, and Mandy Granat, HAEA Health Services Manager, discuss what...

    Credit the people on this episode